OticPharma Establishes U.S. Headquarters in Orange County, California

IRVINE, Calif. and REHOVOT, Israel, Sept. 3, 2015 /PRNewswire/ -- OticPharma, Ltd., a privately held company focused on acquiring and developing innovative therapies for ear, nose, and throat (ENT) disorders, today announced it has selected the Irvine Company's Newport Gateway office complex to be the location of its new U.S. headquarters.  OticPharma plans to complete the move by end of September and will have office locations in both U.S. and Israel.

U.S. Headquarters:

OticPharma, Inc.
19900 MacArthur Blvd., Suite 550
Irvine, California 92612
Tel: +1 (949) 238-8090

Israel Office:

OticPharma, Ltd.
7 Oppenheimer Street, Science Park
Rehovot 7670107, Israel
Tel: +972 (73) 290-3831

"Establishing our U.S. headquarters is the first step in our strategic plan to build a leading ENT company," said Gregory J. Flesher, chief executive officer for OticPharma, Ltd. "We will now focus on the expansion of the U.S. management team as well as the acquisition of additional products that complement our FoamOtic program and address unmet need in both children and adults."

About OticPharma

OticPharma, established in 2008, is a clinical-stage company active in the field of ear, nose, and throat disorders. The company's current product candidates are based on FoamOtic, a proprietary foam-based drug delivery system that provides sustained exposure of drugs.

About FoamOtic

Otic's lead product, FoamOtic Externa, is an investigational proprietary, foam-based, extended-release formulation of ciprofloxacin antibiotic, which has been designated for self-administration, once-daily to potentially treat acute otitis externa (AOE) in minor and adult patients. The company recently completed a successful Phase 2 clinical trial with FoamOtic Externa in minor and adult patients with AOE and is currently planning the Phase 3 program.

About AOE

AOE or "swimmer's ear" is a generalized inflammation of the epithelium of the external ear canal which may also involve the pinna and/or the tympanic membrane. It is variably characterized by erythema, edema, increased sebum or exudates, and desquamation of the epithelium. AOE is a common, worldwide otologic problem occurring in humans mainly during hot and humid weather. The vast majority of the cases of AOE are due to bacterial infections. The common treatment of AOE consists of topical antibiotics, with or without steroids, analgesia and water avoidance. Otic preparations are generally supplied in the form of liquid ear drops which are administered multiple times per day. There are approximately 2.5 million cases of AOE per year in the United States.

Contact

Gregory J. Flesher
Chief Executive Officer
[email protected]
Tel: +1 (949) 238-8090 x700

Logo - http://photos.prnewswire.com/prnh/20150902/263275LOGO

SOURCE OticPharma, Ltd.

Related Links

http://www.oticpharma.com